Chairman and Chief Executive Officer Liang Wenqing increased his shareholding in CF PHARMTECH (02652) by 19,300 shares at approximately HK$6.92 per share.
On October 6, Chairman and Chief Executive Officer Liang Wenqing increased his shareholding in CF PHARMTECH (02652) by 19,300 shares at HK$6.9216 per share, for a total amount of approximately HK$133,600.
The latest data from the Hong Kong Stock Exchange shows that on October 6, Chairman and Chief Executive Officer Liang Wenqing increased his shareholding in CF PHARMTECH (02652) by 19,300 shares at HK$6.9216 per share, for a total amount of approximately HK$133,600. After the increase, his latest shareholding stood at approximately 60,716,500 shares, representing an 18.74% stake.
Supplementary information: Pursuant to Acting-in-Concert Agreement, Dr. LIANG Bill Wenqing and Dr. LI LI BOVET are parties acting in concert. As such, under the SFO, each of Dr. LIANG and Dr. LI LI BOVET is deemed to be interested in the Shares the other is interested in.
Related Articles
.png)
Jiangxi Tungsten Rare and Precious Equipment (600397.SH)'s application for issuing A-shares to specific targets has been accepted by the Shanghai Stock Exchange.
NUOBIKAN (02635) completes placement of a total of 16.4885 million shares, raising approximately HK$131 million net.
STAR SHINE HLDG (01440): Proposed Share Subdivision and Change in Board Lot Size
Jiangxi Tungsten Rare and Precious Equipment (600397.SH)'s application for issuing A-shares to specific targets has been accepted by the Shanghai Stock Exchange.
NUOBIKAN (02635) completes placement of a total of 16.4885 million shares, raising approximately HK$131 million net.
STAR SHINE HLDG (01440): Proposed Share Subdivision and Change in Board Lot Size
